Development of an in vitro alternative assay method for vaginal irritation

Toxicology

Volumn 279, Issue 1-3, 2011, Pages 130-138

  Ayehunie, Seyoum ^a   Cannon, Chris ^a   LaRosa, Karen ^a   Pudney, Jeffrey ^b   Anderson, Deborah J ^b   Klausner, Mitchell ^a  

^a MATTEK CORPORATION   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

EpiVaginal tissue; In vitro assay; Inflammatory cytokines; Vaginal irritation

Indexed keywords

BENZALKONIUM CHLORIDE; FLUORESCEIN SODIUM; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; NONOXINOL 9;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOASSAY; CONTROLLED STUDY; CYTOKINE RELEASE; ELECTRIC RESISTANCE; FEMALE; FEMININE HYGIENE PRODUCT; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN TISSUE; IN VITRO STUDY; MEMBRANE DAMAGE; NONHUMAN; PRIORITY JOURNAL; PUBLIC HEALTH PROBLEM; REPRODUCIBILITY; VAGINA MUCOSA; VAGINITIS;

ADULT; ANIMAL TESTING ALTERNATIVES; ANIMALS; BENZALKONIUM COMPOUNDS; CYTOKINES; DRUG EVALUATION, PRECLINICAL; ELECTRIC IMPEDANCE; FEMALE; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; IRRITANTS; MUCOUS MEMBRANE; NONOXYNOL; RABBITS; REPRODUCIBILITY OF RESULTS; TOXICITY TESTS; VAGINA;

ANIMALIA; HUMAN HERPESVIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS 1; ORYCTOLAGUS CUNICULUS;

EID: 78650005338     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tox.2010.10.001     Document Type: Article

References (37)

1. Achilles S.L., et al. Microbicide efficacy and toxicity tests in a mouse model for vaginal transmission of Chlamydia trachomatis. Sex. Transm. Dis. 2002, 29:655-664.
2. Ayehunie S., et al. Organotypic human vaginal-ectocervical tissue model for irritation studies of spermicides, microbicides, and feminine-care products. Toxicol. in Vitro 2006, 20:689-698.
3. Bamforth S.D., et al. Ultrastructural analysis of interleukin-1beta-induced leukocyte recruitment to the rat retina. Invest. Ophthalmol. Vis. Sci. 1997, 38:25-35.
4. Belec L., et al. Proinflammatory cytokine expression in cervicovaginal secretions of normal and HIV-infected women. Cytokine 1995, 7:568-574.
5. Catalone B.J., et al. Comparative safety evaluation of candidate vaginal microbicide C31G. Antimicrob. Agents Chemother. 2005, 49:1509-1520.
6. Centers for Disease Control and Prevention, August 4, 2000, posting date. Letter from the Director, National Center for HIV, STD, and TB Prevention. http://www.cdc.gov/hiv/pubs/mmwr/mmwr11aug00.htm.
7. Clothier R., et al. Assessment of initial damage and recovery following exposure of MDCK cells to an irritant. Toxicol. in Vitro 1999, 13:713-717.
8. Cole A.L., et al. Herasimtschuk. The retrocyclin analogue RC-101 prevents human immunodeficiency virus type 1 infection of a model human cervicovaginal tissue construct. Immunology 2007, 121:140-145.
9. Cummins J.E., Doncel G. Biomarkers of cervicovaginal inflammation for the assessment of microbicide safety. Sex. Transm. Dis. 2009, 36:S84-S91.
10. Dayal M.B., et al. Disruption of upper female reproductive tract epithelium by nonoxynol-9. Contraception 2003, 68:273-279.
11. D'Cruz O.J., Uckun F.M. Pre-clinical safety evaluation of novel nucleoside analogue-based dual-function microbicides (WHI-05 and WHI-07). J. Antimicrob. Chemother. 2002, 50:793-803.
12. Delvenne P., et al. The organotypic culture of HPV-transformed keratinocytes: an effective in vitro model for the development of new immunotherapeutic approaches for mucosal (pre) neoplastic lesions. Vaccine 2001, 19:2557-2564.
13. Doncel G., et al. Preclinical assessment of the proinflammatory potential of microbicide candidates. J. Acquir. Immune Defic. Syndr. 2004, 37:S174-S180.
14. Dover S.E., et al. Safety study of an antimicrobial peptide lactocin 160, produced by the vaginal lactobacillus rhamnosus. Infect. Dis. Obst. Gynecol. 2007, Article ID #78248.
15. Eckstein P., et al. Comparison of vaginal tolerance tests of spermicidal preparations in rabbits and monkeys. J. Reprod. Fertil. 1969, 20:85-93.
16. Fichorova R.N., et al. Interleukin (IL)-1, IL-6, and IL-8 predict mucosal toxicity of vaginal microbicidal contraceptives. Biol. Reprod. 2004, 71:761-769.
17. Fletcher P.S., et al. Preclinical evaluation of lime juice as a topical microbicide candidate. Retrovirology 2008, 5:3.
18. Galen B.T., et al. A comprehensive murine model to evaluate topical vaginal microbicides: mucosal inflammation and susceptibility to genital herpes as surrogate markers of safety. J. Infect. Dis. 2007, 195:1332-1339.
19. Gali Y., et al. Development of an in vitro dual-chamber model of the female genital tract as a screening tool for epithelial toxicity. J. Virol. Meth. 2010, 165:186-197.
20. Klausner M., et al. Organotypic human oral tissue models for toxicological studies. Toxicol. in Vitro 2007, 21:938-949.
21. Kniewald J., et al. Alternative models for toxicity testing of xenobiotics. Altern. Toxicol. Test. 2005, 56:195-204.
22. Mansergh G., et al. Continued use of Nonoxynol-9 (N9) in a diverse sample of men who have sex with men (MSM) and a potentially effective prevention message to reduce N9 use. Int. Conf. AIDS 2002, 14: abstract no. MoPeD3547.
23. Noguchi K., et al. Qualitative and quantitative differences in normal vaginal flora of conventionally reared mice, rats, hamsters, rabbits, and dogs. Comp. Med. 2003, 53:404-412.
24. Osborn L., et al. Tumor necrosis factor-α and interleukin-1 stimulate the human immunodeficiency virus enhancer by activation of nuclear factor kappa B. Proc. Natl. Acad. Sci. U.S.A. 1989, 86:2336-2340.
25. Passmore J.S., et al. Papanicolaou smears and cervical inflammatory cytokine responses. J. Inflamm. (Lond.) 2007, 4:8.
26. Phillips D.M., et al. Nonoxynol-9 causes rapid exfoliation of sheets of rectal epithelium. Contraception 2000, 62:149-154.
27. Roddy R.E., et al. A dosing study of nonoxynol-9 and genital irritation. Int. J. STD AIDS 1993, 4:165-167.
28. Squier C.A., et al. Procine vagina ex vivo as a model for studying permeability and pathogenesis in mucosa. J. Pharmaceut. Sci. 2007, doi:10.1002/jps.21077.
29. Spielmann, H., et al., 2007. The ECVAM international validation study on in vitro tests for acute skin irritation: report on the validity of the EPISKIN and EpiDerm assays and on the Skin Integrity Function Test. Altern. Lab. Anim. 35, 559-601.
30. Stafford M.K., et al. Safety study of nonoxynol-9 as a vaginal microbicide: evidence of adverse effects. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 1998, 17:327-331.
31. Trifonova R.T., et al. Vaginal formulation - how innocuous are they to the vaginal epithelial immune function?. Am. J. Reprod. Immunol. 2005, 54:121.
32. Tsai C.C., et al. Cyanovirin-N gel as a topical microbicide prevents rectal transmission of SHIV-189. 6P in macaques. AIDS Res. Hum. Retroviruses 2003, 19:535-541.
33. Valore E.V., et al. Reversible deficiency of antimicrobial polypeptides in bacterial vaginosis. Infect. Immun. 2006, 74:5693-5702.
34. Venkataraman N., et al. Cationic polypeptides are required for anti-HIV-1 activity of human vaginal fluid. J. Immunol. 2005, 175:7560-7567.
35. Ward R.K., et al. Evaluation of tissue culture insert membrane compatibility in the fluorescein leakage assay. Toxicol. in Vitro 1997, 11:761-768.
36. Weber J., et al. The development of vaginal microbicides for the prevention of HIV transmission. PLoS Med. 2005, 2(e142):392-395.
37. Zaneveld L.J., et al. Efficacy and safety of a new vaginal contraceptive antimicrobial formulation containing high molecular weight poly (sodium 4-styrenesulfonate). Biol. Reprod. 2002, 66:886-894.